According to the research report, the global biologics contract development market size is expected to touch USD 18.71 Billion by 2032, from USD 6.65 Billion in 2022, growing with a significant CAGR of 10.89% from 2023 to 2032.
Key Takeaways:
- North America is predicted to dominate the global market between 2023 and 2032.
- By Source, the mammalian segment is expected to expand at the fastest CAGR from 2023 to 2032.
- By Indication, the oncology segment is expected to register the largest CAGR from 2023 to 2032.
- By Product Service, the process development segment is expected to expand at the fastest CAGR between 2023 and 2032.
The biologics contract development report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global biologics contract development in conjunction with the geographical landscape of this vertical have also been included in this report.
The report offers intricate dynamics about different aspects of the global biologics contract development market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global biologics contract development during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).
Sample Link @ https://www.precedenceresearch.com/sample/3056
This study covers a detailed segmentation of the global biologics contract development market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global biologics contract development market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.
Key Players
- Abzena Ltd
- AGC Biologics
- Bionova Scientific, Inc.
- BioXcellence
- Curia Global, Inc.
- Fujifilm Diosynth Biotechnologies
- Genscript
- KBI Biopharma
- STC Biologics
- Thermo Fisher Scientific Inc.
- WuXi Biologics
- Boehringer Ingelheim Group
- Samsung Biologics
- Lonza Group
Market Segmentation
By Source
- Microbial
- Mammalian
- Others
By Product Service
- Cell Line Development
- Microbial
- Mammalian
- Others
- Process Development
- Upstream
- Microbial
- Mammalian
- Others
- Downstream
- Impurity, isolation, & identification
- Physicochemical characterization
- Pharmaceutical analysis
- Others
- By Product
- MABs
- Recombinant proteins
- Others
- Upstream
- Others
By Indication
- Oncology
- Immunological disorders
- Cardiovascular disorders
- Hematological disorders
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Research Methodology
The research methodology adopted by analysts for compiling the global biologics contract development report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global biologics contract development market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Biologics Contract Development Market
5.1. COVID-19 Landscape: Biologics Contract Development Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Biologics Contract Development Market, By Source
8.1. Biologics Contract Development Market, by Source, 2023-2032
8.1.1 Microbial
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Mammalian
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Biologics Contract Development Market, By Product Service
9.1. Biologics Contract Development Market, by Product Service, 2023-2032
9.1.1. Cell Line Development
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Process Development
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Biologics Contract Development Market, By Indication
10.1. Biologics Contract Development Market, by Indication, 2023-2032
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Immunological disorders
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Cardiovascular disorders
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Hematological disorders
10.1.4.1. Market Revenue and Forecast (2020-2032)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Biologics Contract Development Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Source (2020-2032)
11.1.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.1.3. Market Revenue and Forecast, by Indication (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Source (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.1.4.3. Market Revenue and Forecast, by Indication (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Source (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.1.5.3. Market Revenue and Forecast, by Indication (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Source (2020-2032)
11.2.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.2.3. Market Revenue and Forecast, by Indication (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Source (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.2.4.3. Market Revenue and Forecast, by Indication (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Source (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.2.5.3. Market Revenue and Forecast, by Indication (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Source (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.2.6.3. Market Revenue and Forecast, by Indication (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Source (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.2.7.3. Market Revenue and Forecast, by Indication (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Source (2020-2032)
11.3.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.3.3. Market Revenue and Forecast, by Indication (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Source (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.3.4.3. Market Revenue and Forecast, by Indication (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Source (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.3.5.3. Market Revenue and Forecast, by Indication (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Source (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.3.6.3. Market Revenue and Forecast, by Indication (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Source (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.3.7.3. Market Revenue and Forecast, by Indication (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Source (2020-2032)
11.4.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.4.3. Market Revenue and Forecast, by Indication (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Source (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.4.4.3. Market Revenue and Forecast, by Indication (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Source (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.4.5.3. Market Revenue and Forecast, by Indication (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Source (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.4.6.3. Market Revenue and Forecast, by Indication (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Source (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.4.7.3. Market Revenue and Forecast, by Indication (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Source (2020-2032)
11.5.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.5.3. Market Revenue and Forecast, by Indication (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Source (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.5.4.3. Market Revenue and Forecast, by Indication (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Source (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Product Service (2020-2032)
11.5.5.3. Market Revenue and Forecast, by Indication (2020-2032)
Chapter 12. Company Profiles
12.1. Abzena Ltd
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. AGC Biologics
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Bionova Scientific, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. BioXcellence
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Curia Global, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Fujifilm Diosynth Biotechnologies
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Genscript
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. KBI Biopharma
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. STC Biologics
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Thermo Fisher Scientific Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments